Arcturus Therapeutics' SWOT analysis: mRNA innovator's stock faces pivotal year
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT), a commercial-stage biotechnology company with a market capitalization of $428 million specializing in mRNA therapeutics and vaccines, stands at a ...
Hosted on MSN45m
Zenas BioPharma initiated with an Outperform at Wolfe Research
Wolfe Research initiated coverage of Zenas BioPharma (ZBIO) with an Outperform rating and $19 price target After its IPO in September 2024, the ...